HC Wainwright Has Positive Forecast for ATXS FY2024 Earnings

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Stock analysts at HC Wainwright lifted their FY2024 earnings estimates for Astria Therapeutics in a research report issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per share of ($1.74) for the year, up from their previous forecast of ($1.82). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Astria Therapeutics’ Q4 2024 earnings at ($0.50) EPS, FY2025 earnings at ($1.75) EPS, FY2026 earnings at ($1.88) EPS, FY2027 earnings at ($1.93) EPS and FY2028 earnings at ($1.62) EPS.

Several other equities research analysts have also recently weighed in on the company. Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Wedbush reaffirmed an “outperform” rating and issued a $22.00 target price on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Oppenheimer lifted their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. Finally, TD Cowen started coverage on shares of Astria Therapeutics in a report on Monday, July 29th. They issued a “buy” rating and a $35.00 price objective on the stock. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Astria Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Stock Performance

Shares of NASDAQ:ATXS opened at $9.16 on Monday. The firm has a market capitalization of $516.94 million, a P/E ratio of -4.38 and a beta of 0.71. The stock has a 50 day moving average price of $11.36 and a 200-day moving average price of $10.62. Astria Therapeutics has a 52-week low of $4.41 and a 52-week high of $16.90.

Hedge Funds Weigh In On Astria Therapeutics

Several large investors have recently modified their holdings of the stock. Quest Partners LLC increased its stake in Astria Therapeutics by 3,310.6% during the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 3,112 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in shares of Astria Therapeutics by 135.6% in the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock worth $70,000 after buying an additional 2,861 shares in the last quarter. PDT Partners LLC purchased a new stake in shares of Astria Therapeutics during the third quarter valued at approximately $140,000. SG Americas Securities LLC bought a new stake in shares of Astria Therapeutics during the third quarter valued at approximately $155,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in Astria Therapeutics in the 1st quarter worth approximately $200,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.